GENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026

Bulletin Express06-01 23:03

Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.

Legend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:

1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC). 2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.

Both data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.

Management advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157001185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157001185","market":"hk","top_or_hot":-1,"title":"GENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.</p>\n<p>Legend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:</p>\n<p>1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).  \n2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.</p>\n<p>Both data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.</p>\n<p>Management advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO discloses Legend Biotech’s first-in-human LB2102 CAR-T results and new CARVYKTI® data presented at ASCO 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.</p>\n<p>Legend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:</p>\n<p>1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).  \n2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.</p>\n<p>Both data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.</p>\n<p>Management advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1157001185","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157001185","pubTimestamp":1780326204,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation. Legend Biotech filed a Form...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物披露传奇生物首次人体LB2102 CAR-T结果及新CARVYKTI®ASCO 2026上公布的数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO) issued a voluntary announcement on 1 June 2026 detailing R&D progress reported by its associate, Legend Biotech Corporation.\nLegend Biotech filed a Form 6-K with the U.S. Securities and Exchange Commission and released a concurrent press statement highlighting:\n1. First-in-human clinical data for LB2102, a DLL3-targeted CAR-T cell therapy, in patients with relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).  \n2. New analyses from the CARTITUDE program featuring CARVYKTI®, its B-cell maturation antigen-directed CAR-T therapy for multiple myeloma.\nBoth data sets were presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting.\nManagement advised shareholders and potential investors to remain aware of market risks and exercise caution when trading the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157001185","isCrawlerRequest":true}